Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK44459 in Progressive Pulmonary Fibrosis
NCT07503587Phase 3Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of HSK44459 in pulmonary fibrosis (PF), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
HSK44459
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT07503587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503587.